Similarly, Celastrol's ability to inhibit NF-κB activity in a type 2 diabetic animal model serves yet another example of Celatrol's therapeutic role in transiently lowering blood glucose levels and inhibiting insulin resistance and diabetic nephropathy (40). This evidence concerns the gene NFKB1 and diabetic kidney disease.